Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
P/E ratio for Sol-Gel Technologies Ltd. (SLGL)
P/E ratio as of 2023: -1.10
According to Sol-Gel Technologies Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.10. At the end of 2022 the company had a P/E ratio of -7.75.
P/E ratio history for Sol-Gel Technologies Ltd. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.10 |
| 2022 | -7.75 |
| 2021 | 39.16 |
| 2020 | -8.07 |
| 2019 | -13.61 |
| 2018 | -3.34 |
| 2017 | -7.77 |
| 2016 | -7.71 |
| 2015 | -16.57 |
| 2014 | -7.54 |